Cefovecin

Cefovecin
Cefovecin
Systematic (IUPAC) name
(7R)-7-([(2Z)- 2-(2-amino- 1,3-thiazol- 4-yl)- 2-methoxyiminoacetyl]amino)- 8-oxo- 3-[(2S)-oxolan- 2-yl]- 5-thia- 1-azabicyclo[4.2.0]oct- 2-ene- 2-carboxylic acid
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat. do not administer to pregnant cat or during breeding or lactation period.
Legal status veterinary prescription only
Routes subcutaneous
Pharmacokinetic data
Metabolism non metabolised by the liver
Half-life half life ellimination in cats is 7 days
Excretion mostly excreted unchanged in the urine.
Identifiers
CAS number 234096-34-5
ATCvet code QJ01DD91
PubChem CID 9578573
UNII 0D1OL46ZIE YesY
Chemical data
Formula C17H19N5O6S2 
Mol. mass 453.49 g/mol
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

Cefovecin (INN) is an antibiotic of the cephalosporin class, licensed for the treatment of skin infections in cats and dogs. It is marketed by Pfizer under the trade name Convenia.

Approval and usage

Cefovecin was first authorized for use in the European Union on June 2006.[1] It was not approved for use in the United States until June 2008.[2]

References

  1. ^ "European Public Assessment Report for Convenia (from the EMEA website)". http://www.emea.europa.eu/vetdocs/vets/Epar/convenia/convenia.htm. Retrieved 2008-07-11. 
  2. ^ "FDA Approves First and Only Single-Dose Antibiotic for Dogs and Cats" (Press release). Pfizer Inc.. 2008-06-30. http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20080630005686&newsLang=en. Retrieved 2008-07-11. 

External links


Stub icon This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it. This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it.